Cost-effectiveness of ranibizumab for the treatment of neovascular age-related macular degeneration in germany: Model analysis from the perspective of germany's statutory health insurance system (Q84634381)

From Wikidata

Jump to navigation Jump to search

scientific article published on 01 July 2010

Language	Label	Description	Also known as
English	Cost-effectiveness of ranibizumab for the treatment of neovascular age-related macular degeneration in germany: Model analysis from the perspective of germany's statutory health insurance system	scientific article published on 01 July 2010

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20678682%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Cost-effectiveness of ranibizumab for the treatment of neovascular age-related macular degeneration in Germany: Model analysis from the perspective of Germany's statutory health insurance system (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20678682%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Cost-effectiveness of ranibizumab for the treatment of neovascular age-related macular degeneration in germany: Model analysis from the perspective of germany's statutory health insurance system (English)

1 reference

10.1016/J.CLINTHERA.2010.07.010

https://api.crossref.org/works/10.1016/J.CLINTHERA.2010.07.010

15 June 2024

macular degeneration

1 reference

based on heuristic

inferred from title

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20678682

15 June 2024

author name string

Stefan Sauer

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20678682%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Timo Wasmuth

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20678682%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Christoph Hirneiss

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20678682%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Anselm Kampik

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20678682%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Wolfgang Schrader

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20678682%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Aljoscha S. Neubauer

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20678682

15 June 2024

Frank G. Holz

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20678682

15 June 2024

language of work or name

1 reference

National Center for Biotechnology Information

PubMed publication ID

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20678682

15 June 2024

publication date

1 July 2010

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20678682%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

full work available at URL

https://api.elsevier.com/content/article/PII:S0149291810002377?httpAccept=text/xml

1 reference

10.1016/J.CLINTHERA.2010.07.010

https://api.crossref.org/works/10.1016/J.CLINTHERA.2010.07.010

15 June 2024

https://api.elsevier.com/content/article/PII:S0149291810002377?httpAccept=text/plain

1 reference

10.1016/J.CLINTHERA.2010.07.010

https://api.crossref.org/works/10.1016/J.CLINTHERA.2010.07.010

15 June 2024

Clinical Therapeutics

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20678682%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

32

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20678682%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20678682%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

1343-1356

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20678682%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Burden of illness, visual impairment and health resource utilisation of patients with neovascular age-related macular degeneration: results from the UK cohort of a five-country cross-sectional study

1

1 reference

10.1016/J.CLINTHERA.2010.07.010

https://api.crossref.org/works/10.1016/J.CLINTHERA.2010.07.010

15 June 2024

Burden and health care resource utilization in neovascular age-related macular degeneration: findings of a multicountry study.

2

1 reference

10.1016/J.CLINTHERA.2010.07.010

https://api.crossref.org/works/10.1016/J.CLINTHERA.2010.07.010

15 June 2024

[Blindness in Germany--today and in 2030]

4

1 reference

10.1016/J.CLINTHERA.2010.07.010

https://api.crossref.org/works/10.1016/J.CLINTHERA.2010.07.010

15 June 2024

Age-related macular degeneration: a socioeconomic time bomb in our aging society

6

1 reference

10.1016/J.CLINTHERA.2010.07.010

https://api.crossref.org/works/10.1016/J.CLINTHERA.2010.07.010

15 June 2024

Ranibizumab versus verteporfin for neovascular age-related macular degeneration.

10

1 reference

10.1016/J.CLINTHERA.2010.07.010

https://api.crossref.org/works/10.1016/J.CLINTHERA.2010.07.010

15 June 2024

Ranibizumab for neovascular age-related macular degeneration

11

1 reference

10.1016/J.CLINTHERA.2010.07.010

https://api.crossref.org/works/10.1016/J.CLINTHERA.2010.07.010

15 June 2024

Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study

12

1 reference

10.1016/J.CLINTHERA.2010.07.010

https://api.crossref.org/works/10.1016/J.CLINTHERA.2010.07.010

15 June 2024

Cost-effectiveness of ranibizumab compared with pegaptanib in neovascular age-related macular degeneration

13

1 reference

10.1016/J.CLINTHERA.2010.07.010

https://api.crossref.org/works/10.1016/J.CLINTHERA.2010.07.010

15 June 2024

Ranibizumab and pegaptanib for the treatment of age-related macular degeneration: a systematic review and economic evaluation

14

1 reference

10.1016/J.CLINTHERA.2010.07.010

https://api.crossref.org/works/10.1016/J.CLINTHERA.2010.07.010

15 June 2024

Ranibizumab and pegaptanib for the treatment of age-related macular degeneration: a systematic review and economic evaluation

15

1 reference

10.1016/J.CLINTHERA.2010.07.010

https://api.crossref.org/works/10.1016/J.CLINTHERA.2010.07.010

15 June 2024

A value-based medicine comparison of interventions for subfoveal neovascular macular degeneration

16

1 reference

10.1016/J.CLINTHERA.2010.07.010

https://api.crossref.org/works/10.1016/J.CLINTHERA.2010.07.010

15 June 2024

How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations

17

1 reference

10.1016/J.CLINTHERA.2010.07.010

https://api.crossref.org/works/10.1016/J.CLINTHERA.2010.07.010

15 June 2024

Cost-effectiveness sequential modeling of ranibizumab versus usual care in age-related macular degeneration.

18

1 reference

10.1016/J.CLINTHERA.2010.07.010

https://api.crossref.org/works/10.1016/J.CLINTHERA.2010.07.010

15 June 2024

The comparative effectiveness and cost-effectiveness of vitreoretinal interventions

19

1 reference

10.1016/J.CLINTHERA.2010.07.010

https://api.crossref.org/works/10.1016/J.CLINTHERA.2010.07.010

15 June 2024

Quality of life in patients with age-related macular degeneration with monocular and binocular legal blindness

20

1 reference

10.1016/J.CLINTHERA.2010.07.010

https://api.crossref.org/works/10.1016/J.CLINTHERA.2010.07.010

15 June 2024

Utility values associated with blindness in an adult population

21

1 reference

10.1016/J.CLINTHERA.2010.07.010

https://api.crossref.org/works/10.1016/J.CLINTHERA.2010.07.010

15 June 2024

Comparative effectiveness

22

1 reference

10.1016/J.CLINTHERA.2010.07.010

https://api.crossref.org/works/10.1016/J.CLINTHERA.2010.07.010

15 June 2024

Comparative effectiveness: its role in the healthcare system

23

1 reference

10.1016/J.CLINTHERA.2010.07.010

https://api.crossref.org/works/10.1016/J.CLINTHERA.2010.07.010

15 June 2024

Utility values and age-related macular degeneration.

24

1 reference

10.1016/J.CLINTHERA.2010.07.010

https://api.crossref.org/works/10.1016/J.CLINTHERA.2010.07.010

15 June 2024

Determinants of health related quality of life and health state utility in patients with age related macular degeneration: the association of contrast sensitivity and visual acuity

25

1 reference

10.1016/J.CLINTHERA.2010.07.010

https://api.crossref.org/works/10.1016/J.CLINTHERA.2010.07.010

15 June 2024

Using contrast sensitivity to estimate the cost-effectiveness of verteporfin in patients with predominantly classic age-related macular degeneration

26

1 reference

10.1016/J.CLINTHERA.2010.07.010

https://api.crossref.org/works/10.1016/J.CLINTHERA.2010.07.010

15 June 2024

[Cost-utility analysis of ranibizumab (Lucentis) in neovascular macular degeneration]

27

1 reference

10.1016/J.CLINTHERA.2010.07.010

https://api.crossref.org/works/10.1016/J.CLINTHERA.2010.07.010

15 June 2024

Correlation of high-definition optical coherence tomography and fluorescein angiography imaging in neovascular macular degeneration.

28

1 reference

10.1016/J.CLINTHERA.2010.07.010

https://api.crossref.org/works/10.1016/J.CLINTHERA.2010.07.010

15 June 2024

Monitoring of AMD patients on anti-vascular endothelial growth factor (VEGF) treatment. Practical notes on functional and anatomical examination parameters from drug approval studies, specialist information and case series

30

1 reference

10.1016/J.CLINTHERA.2010.07.010

https://api.crossref.org/works/10.1016/J.CLINTHERA.2010.07.010

15 June 2024

An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration

32

1 reference

10.1016/J.CLINTHERA.2010.07.010

https://api.crossref.org/works/10.1016/J.CLINTHERA.2010.07.010

15 June 2024

A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study

33

1 reference

10.1016/J.CLINTHERA.2010.07.010

https://api.crossref.org/works/10.1016/J.CLINTHERA.2010.07.010

15 June 2024

Economic burden of bilateral neovascular age-related macular degeneration: multi-country observational study

34

1 reference

10.1016/J.CLINTHERA.2010.07.010

https://api.crossref.org/works/10.1016/J.CLINTHERA.2010.07.010

15 June 2024

What is the cost of blindness?

35

1 reference

10.1016/J.CLINTHERA.2010.07.010

https://api.crossref.org/works/10.1016/J.CLINTHERA.2010.07.010

15 June 2024

Neovascular age-related macular degeneration in Germany. Encroachment on the quality of life and the financial implications

37

1 reference

10.1016/J.CLINTHERA.2010.07.010

https://api.crossref.org/works/10.1016/J.CLINTHERA.2010.07.010

15 June 2024

The cost-utility of photodynamic therapy in eyes with neovascular macular degeneration--a value-based reappraisal with 5-year data

39

1 reference

10.1016/J.CLINTHERA.2010.07.010

https://api.crossref.org/works/10.1016/J.CLINTHERA.2010.07.010

15 June 2024

Early clinical experience with ranibizumab for occult and minimally classic neovascular membranes in age-related macular degeneration

40

1 reference

10.1016/J.CLINTHERA.2010.07.010

https://api.crossref.org/works/10.1016/J.CLINTHERA.2010.07.010

15 June 2024

Ranibizumab: Phase III clinical trial results

41

1 reference

10.1016/J.CLINTHERA.2010.07.010

https://api.crossref.org/works/10.1016/J.CLINTHERA.2010.07.010

15 June 2024

Computerized model of cost-utility analysis for treatment of age-related macular degeneration

42

1 reference

10.1016/J.CLINTHERA.2010.07.010

https://api.crossref.org/works/10.1016/J.CLINTHERA.2010.07.010

15 June 2024

Cost utility of photodynamic therapy for predominantly classic neovascular age related macular degeneration

43

1 reference

10.1016/J.CLINTHERA.2010.07.010

https://api.crossref.org/works/10.1016/J.CLINTHERA.2010.07.010

15 June 2024

Incremental cost effectiveness of laser photocoagulation for subfoveal choroidal neovascularization

44

1 reference

10.1016/J.CLINTHERA.2010.07.010

https://api.crossref.org/works/10.1016/J.CLINTHERA.2010.07.010

15 June 2024

CME review: A cost-utility analysis of laser photocoagulation for extrafoveal choroidal neovascularization

45

1 reference

10.1016/J.CLINTHERA.2010.07.010

https://api.crossref.org/works/10.1016/J.CLINTHERA.2010.07.010

15 June 2024

CME review: A cost-utility analysis of laser photocoagulation for extrafoveal choroidal neovascularization

46

1 reference

10.1016/J.CLINTHERA.2010.07.010

https://api.crossref.org/works/10.1016/J.CLINTHERA.2010.07.010

15 June 2024

A value-based medicine analysis of ranibizumab for the treatment of subfoveal neovascular macular degeneration

47

1 reference

10.1016/J.CLINTHERA.2010.07.010

https://api.crossref.org/works/10.1016/J.CLINTHERA.2010.07.010

15 June 2024

A cost-effectiveness analysis of three treatments for age-related macular degeneration

48

1 reference

10.1016/J.CLINTHERA.2010.07.010

https://api.crossref.org/works/10.1016/J.CLINTHERA.2010.07.010

15 June 2024

Quality of life associated with unilateral and bilateral good vision

49

1 reference

10.1016/J.CLINTHERA.2010.07.010

https://api.crossref.org/works/10.1016/J.CLINTHERA.2010.07.010

15 June 2024

Quality of life associated with unilateral and bilateral good vision

50

1 reference

10.1016/J.CLINTHERA.2010.07.010

https://api.crossref.org/works/10.1016/J.CLINTHERA.2010.07.010

15 June 2024

Identifiers

10.1016/J.CLINTHERA.2010.07.010

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20678682%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20678682%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q84634381&oldid=2180031357"